Tyme Technologies, Inc. (TYME) News
Filter TYME News Items
TYME News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
TYME News Highlights
- TYME's 30 day story count now stands at 10.
- Over the past 24 days, the trend for TYME's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
- SM, ROSE and SECO are the most mentioned tickers in articles about TYME.
Latest TYME News From Around the Web
Below are the latest news stories about Tyme Technologies Inc that investors may wish to consider to help them evaluate TYME as an investment opportunity.
The Tyme Technologies Inc. (NASDAQ: TYME) Stock Price: Is It Overvalued?Tyme Technologies Inc. (NASDAQ:TYME) shares, rose in value on Friday, 02/18/22, with the stock price down by -0.32% to the previous days close as strong demand from buyers drove the stock to $0.34. Actively observing the price movement in the last trading, the stock closed the session at $0.34, falling within a range of $0.3305 The Tyme Technologies Inc. (NASDAQ: TYME) Stock Price: Is It Overvalued? Read More » |
TYME Technologies, Inc. Provides Business Update and Announces Third Fiscal Quarter 2022 Financial and Operating ResultsTYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), |
Tyme Technologies, Inc.''s (TYME) CEO Richie Cunningham on Q3 2022 Results - Earnings Call TranscriptNo summary available. |
Tyme Technologies GAAP EPS of -$0.03Tyme Technologies press release (TYME): FQ3 GAAP EPS of -$0.03.The company is on track for mid-2022 full enrollment of HopES trial for SM-88 used in patients with high-risk Ewing’s… |
TYME Technologies, Inc. to Host Conference Call and Webcast on Friday, February 11, at 8:30 AM ETBEDMINSTER, N.J., January 27, 2022--TYME Technologies, Inc. (Nasdaq: TYME) (the "Company" or "TYME"), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that the Company will report its third quarter 2022 financial results on Friday, February 11, 2022, at 8:30 AM ET. |
Why Are Tyme Technologies Shares Staring At 52-Week LowTYME Technologies Inc (NASDAQ: TYME ) will discontinue SM-88 with MPS in the Precision Promise trial in metastatic pancreatic cancer (mPDAC). The trial''s sponsor, Pancreatic Cancer Action Network (PanCAN), terminated the arm due to futility compared to the control of the standard of Full story available on Benzinga.com |
TYME Technologies, Inc. Provides Update on Precision Promise Trial in Metastatic Pancreatic CancerBEDMINSTER, N.J., January 26, 2022--TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced the discontinuation of SM-88 with MPS in the Precision Promise trial in metastatic pancreatic cancer (mPDAC) upon learning from the trial sponsor, Pancreatic Cancer Action Network (PanCAN), that it terminated the arm due to futility compared to the control of standard of care chemotherapy in seco |
TYME Technologies, Inc. to Present at H.C. Wainwright Bioconnect Virtual ConferenceBEDMINSTER, N.J., January 03, 2022--TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that Richie Cunningham, Chief Executive Officer, and Jonathan Eckard, Chief Business Officer, will present at the H.C. Wainwright Bioconnect Virtual Conference as follows: |
Tyme Technologies Inc. (NASDAQ: TYME)s Stock Is Down -38.25% Since The Beginning Of The Year, Likely To Sustain The Trend In 2021During the last session, Tyme Technologies Inc. (NASDAQ:TYME)s traded shares were 0.79 million, with the beta value of the company hitting 0.92. At the end of the trading day, the stocks price was $0.70, reflecting an intraday loss of -0.85% or -$0.01. The 52-week high for the TYME share is $4.99, that puts it down Tyme Technologies Inc. (NASDAQ: TYME)s Stock Is Down -38.25% Since The Beginning Of The Year, Likely To Sustain The Trend In 2021 Read More » |
TYME Technologies, Inc. Announces Additional Encouraging Preclinical Data on the Effect of TYME-19 in SARS CoV-2 InfectionsBEDMINSTER, N.J.--(BUSINESS WIRE)--TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced encouraging preclinical data on the effect of TYME-19 in SARS CoV-2 infections. The Company believes that TYME-19, a synthetic bile acid, may have differentiated mechanisms that could offer alternatives for COVID-19 infected patients who may not be served by current and emerging oral agents. Bile |